Skip main navigation
×

You do not have any saved searches

  • Serum Chitotriosidase Activity Is Increased in Subjects With Atherosclerosis Disease

  • Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene Mutation

  • The Use of Achilles Tendon Sonography to Distinguish Familial Hypercholesterolemia from Other Genetic Dyslipidemias

  • Femoral Atherosclerosis In Heterozygous Familial Hypercholesterolemia: Influence Of The Genetic Defect

  • Toxic Metals and Subclinical Atherosclerosis in Carotid, Femoral, and Coronary Vascular Territories: The Aragon Workers Health Study

  • Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia

  • Abstract 858: Increase in High-Density Lipoprotein Cholesterol is Not Related With Higher Non-Cardiovascular Mortality; Systematic Review and Meta-Regression Analysis

  • Abstract 1613: Predictors of Lipid Lowering Response to Weight Loss in Familial Hyperlipidemias

  • Abstract 18248: Apolipoprotein E Gene Mutations in Subjects with Mixed Hyperlipoproteinemia and a Clinical Diagnosis of Familial Combined Hyperlipidemia

  • Abstract 13801: The p.Leu167del Mutation in APOE Gene causes Autosomal Dominant Hypercholesterolemia by Down-Regulation of LDL Receptor Expression in Hepatocytes

  • Abstract 15011: Genetic Variants in ABCG5/G8 Are Associated With Primary Hypercholesterolemia

  • Abstract 14769: Femoral Plaque Presence by Ultrasound Provides Discriminative Capacity for MACE beyond Cardiovascular Risk Factors: The Aragon Workers’ Health Study (AWHS)

  • Genetic Variants in CCNB1 Associated With Differential Gene Transcription and Risk of Coronary In-Stent Restenosis

  • Common Genetic Variants Contribute to Primary Hypertriglyceridemia Without Differences Between Familial Combined Hyperlipidemia and Isolated Hypertriglyceridemia

  • Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype–Genotype Relationship

  • Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

    and for the OSLER Investigators
  • Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study

  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

    and the ODYSSEY CHOICE II Investigators